Royalty and licence payments

A small group of physicians at the very top of the data, for a reason that surprises people.

Sort any large slice of Open Payments by value and the top is not dominated by speakers. It is dominated by inventors.

Why the numbers are so large

An orthopaedic surgeon who designed a knee implant receives a royalty on units sold. A spine surgeon whose fixation system is used nationally can receive seven figures a year. These are patent-licence payments, contractually owed, of the same character as any inventor’s royalty.

Why it still matters

The conflict is genuine and specific: a surgeon earning a royalty on a device has a direct financial interest in choosing it. Most academic centres require disclosure to the patient and, in some cases, recusal from device-selection committees. Some require the surgeon to waive royalties on their own cases.

How to read it

A royalty line is not a marketing payment and should not be totalled alongside meals as if it were. DocDollars flags royalty-dominated profiles explicitly in the characterisation line, because presenting a patent income stream as “pharma money” is a category error.